ПРОФИЛАКТИКА СЕРДЕЧНО-СОСУДИСТЫХ ЗАБОЛЕВАНИЙ  В ПОЖИЛОМ ВОЗРАСТЕ (ОБЗОР ЛИТЕРАТУРЫ)

S.M. Mamatov; M.M. Murzaibragimova; M.A. Arstanbekova; D.K. Smailova

doi:10.54890/1694-8882-2024-5-41

S.M. Mamatov M.M. Murzaibragimova M.A. Arstanbekova D.K. Smailova

DOI:

https://doi.org/10.54890/1694-8882-2024-5-41

Abstract

Life expectancy has increased significantly in recent decades. In this scenario, healthcare interventions are needed to improve the prognosis and quality of life of older adults with cardiovascular risk factors and cardiovascular disease. However, the number of older patients included in clinical trials is small, so current clinical practice guidelines do not include specific recommendations. The aim of this document is to review preventive recommendations targeting
patients ≥ 75 years old with high or very high cardiovascular risk regarding goals, medical treatment options, and including physical exercise and its inclusion in cardiac rehabilitation programs. In addition, it is shown why geriatric syndromes such as frailty, dependence, cognitive impairment and nutritional status, as well as comorbidities, should be considered in this population in terms of their important prognostic impact. It is important to assess the most common comorbidities, including anemia, which is often identified in older age, and the mental status of patients, as depression iscommon in this population and may be confused with or overlap with cognitive impairment, increasing complications and cardiovascular morbidity and mortality.

Keywords:

cardiovascular system, old age, prevention

Author Biographies

S.M. Mamatov, Kyrgyz State Medical Academy named after I.K. Akhunbaev

Department of Hospital Therapy with the Course of Hematology

M.M. Murzaibragimova, Kyrgyz State Medical Academy named after I.K. Akhunbaev

Department of Hospital Therapy with the Course of Hematology

M.A. Arstanbekova, Kyrgyz State Medical Academy named after I.K. Akhunbaev

Department of Hospital Therapy with the Course of Hematology

D.K. Smailova, Kyrgyz State Medical Academy named after I.K. Akhunbaev

Department of Hospital Therapy with the Course of Hematology

References

1. INE. National Statistics Institute. INE. 2024. Available from: https://www.ine.es/dyngs/INEbase/en/operacion.htm?c=Estadistica_C&cid=1254736177004&m enu= ultiDatos&idp=1254735573002.

2. Madhavan MV, Gersh BJ, Alexander KP, Granger CB, Stone GW. Coronary Artery Disease in Patients ≥80 Years of Age. J Am Coll Cardiol. 2018;71(18):2015-2040. https://doi.org/10.1016/j.jacc.2017.12.068

3. Díez-Villanueva P, Arizá-Solé A, Vidán MT, Bonanad C, Formiga F, Sanchis J, et al. Recommendations of the Geriatric Cardiology Section of the Spanish Society of Cardiology for the Assessment of Frailty in Elderly Patients With Heart Disease. Rev Esp Cardiol (Engl Ed). 2019;72(1):63-71. https://doi.org/10.1016/j.rec.2018.06.035

4. Mortensen MB, Nordestgaard BG. Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70-100 years: a contemporary primary prevention cohort. Lancet. 2020;396(10263):1644-1652. https://doi.org/10.1016/S0140-6736(20)32233-9

5. Gencer B, Marston NA, Im K, Cannon C P, Sever P, Keech A, et al. Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. Lancet. 2020;396(10263):1637-1643. https://doi.org/10.1016/S0140-6736(20)32332-1

6. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk [published correction appears in Eur Heart J. 2020 Nov 21;41(44):4255. doi: 10.1093/eurheartj/ehz826]. Eur Heart J. 2020;41(1):111-188. https://doi.org/10.1093/ eurheartj/ehz455

7. Sinnaeve PR, Schwartz GG, Wojdyla DM, Alings M, Bhatt DL, Bittner VA, et al. Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis. Eur Heart J. 2020;41(24):2248-2258. https://doi.org/10.1093/eurheartj/ehz809

8. Ballantyne CM, Laufs U, Ray KK, Leiter LA, Bays HE, Goldberg AC, et al. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. Eur J Prev Cardiol. 2020;27(6):593−603. https://doi.org/10.1177/ 2047487319864671

9. Yusuf S., Hawken S., Ounpuu S. Dans, T., Avezum, A., Lanas, F., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): casecontrol study. Lancet 2004;364(9438): 937−952. https://doi.org/10.1016/S0140-6736(04)17018-9

10. SPRINT Research Group, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control [published correction appears in N Engl J Med. 2017 Dec 21;377(25):2506. https://doi.org/10.1056/NEJMx170008]. N Engl J Med. 2015;373(22):2103-2116. https://doi.org/10.1056/NEJMoa1511939

11. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension [published correction appears in Eur Heart J. 2019 Feb 1;40(5):475. https://doi.org/10.1093/eurheartj/ehy686]. Eur Heart J. 2018;39(33):3021-3104. https://doi.org/10.1093/ eurheartj/ehy339

12. Windle SB, Bata I, Madan M, Abramson BL, Eisenberg MJ. A randomized controlled trial of the efficacy and safety of varenicline for smoking cessation after acute coronary syndrome: design and methods of the Evaluation of Varenicline in Smoking Cessation for Patients Post-Acute Coronary Syndrome trial. Am Heart J. 2015;170(4):635-640.e1. https://doi.org/ 10.1016/j.ahj.2015.07.010

13. Collet J-P, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes in patients presenting with out persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2021;42(19):1289-1367. https://doi.org/10.1093/eurheartj/ehaa895

14. Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coron- ary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39(3):213−260. https://doi.org/10.1093/eurheartj/ehx419

15. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001-2015. https://doi.org/10.1056/NEJMoa0706482

16. Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. NEngl J Med. 2015;372(19):1791-1800. https://doi.org/10.1056/NEJMoa1500857

17. Sanchis J, Soler M, Núñez J, Ruiz V, Bonanad C, Formiga F, et al. Comorbidity assessment for mortality risk stratification in elderly patients with acute coronary syndrome. Eur J Intern Med. 2019;62:48−53. https://doi.org/10.1016/j. ejim.2019.01.018

18. Linn BS, Linn MW, Gurel L. Cumulative illness rating scale. J Am Geriatr Soc. 1968;16(5):622-626. https://doi.org/ 10.1111/j.1532-5415.1968.tb02103.x

19. Bureau ML, Liu E, Christiaens L, Pilotto A, Mergy J, Bellarbre F, et al. Using a multidimensional prognostic index (MPI) based on comprehensive geriatric assessment (CGA) to predict mortality in elderly undergoing transcatheter aortic valve im- JOURNAL OF GERIATRIC CARDIOLOGY REVIEW plantation. Int J Cardiol. 2017;236:381-386. https://doi.org/10.1016 /j.ijcard.2017.02.048

20. Morley JE, Vellas B, van Kan GA, Anker SD, Bauer JM, Bernabei R, et al. Frailty consensus: a call to action. J Am Med Dir Assoc. 2013;14(6):392−397. https://doi.org/10.1016/j.jamda.2013.03.022

21. O'Mahony D, O'Sullivan D, Byrne S, O'Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2 [published correction appears in Age Ageing. 2018 May 1;47(3):489. https://doi.org/10.1093/ageing/afx178]. Age Ageing. 2015;44(2):213-218. https://doi.org/ 10.1093/ageing/afu145

22. Тажибаева У.Ж., Арстанбекова М.А., Мусакеев А.К. Нартаева А.К., Иманалиева Ф.Э., Маматов С.М. Патофизиологические аспекты и лечение дефицита железа у пожилых людей (обзор литературы). Вестник КГМА им И.К. Ахунбаева. 2023;2:65-72. https://doi.org/10.54890/1694-6405_2023_2_65

23. Castellano JM, Sanz G, Peñalvo JL, Bansilal S, Fernández-Ortiz A, Alvarez L, et al. A polypill strategy to improve adherence: results from the FOCUS project. J Am Coll Cardiol. 2014;64(20):2071−2082. https://doi.org/10.1016/j.jacc.2014 .08.021

24. Anderson L, Oldridge N, Thompson DR, Zwisler AD, Rees K, Martin N, et al. Exercise-based cardiac rehabilitation for coronary heart disease: Cochrane systematic review and meta-analysis. J Am Coll Cardiol. 2016;67(1):1−12. https://doi.org/10.1016/j.jacc.2015.10.044

25. Vanhees L, De Sutter J, Gelada SN, Doyle F, Prescott E, Cornelissen V, et al. Importance of characteristics and modalities of physical activity and exercise in defining the benefits to cardiovascular health within the general population: recommendations from the EACPR (Part I). Eur J Prev Cardiol. 2012;19(4):670-686. https://doi.org/10.1177/20474873124 37059

26. Brown TM, Hernandez AF, Bittner V, Cannon CP, Ellrodt G, Liang L, et al. Predictors of cardiac rehabilitation referral in coronary artery disease patients: findings from the American Heart Association's get with the guidelines program. J Am Coll Cardiol. 2009;54(6):515-521. https://doi.org/10.1016/j.jacc.2009.02.080